Cargando…

The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia

OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment....

Descripción completa

Detalles Bibliográficos
Autores principales: Hull, Barbara, Wędrychowicz, Anna, Ossowska, Magdalena, Furtak, Aleksandra, Badacz, Joanna, Skoczeń, Szymon, Starzyk, Jerzy B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724047/
https://www.ncbi.nlm.nih.gov/pubmed/35633644
http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2
_version_ 1784844324621516800
author Hull, Barbara
Wędrychowicz, Anna
Ossowska, Magdalena
Furtak, Aleksandra
Badacz, Joanna
Skoczeń, Szymon
Starzyk, Jerzy B.
author_facet Hull, Barbara
Wędrychowicz, Anna
Ossowska, Magdalena
Furtak, Aleksandra
Badacz, Joanna
Skoczeń, Szymon
Starzyk, Jerzy B.
author_sort Hull, Barbara
collection PubMed
description OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment. METHODS: Forty-three ALL survivors, mean age 8.5±3.6 years and 45 age and sex-matched healthy controls were recruited to the study. ALL patients were assessed once within five years following oncological treatment completion. Fasting blood samples were collected from all participants to measure: fasting blood glucose (FBG); cortisol; aldosterone; plasma renin activity (PRA); dehydroepiandrostendione-sulfate (DHEA-S); and adrenocorticotropic hormone (ACTH). Moreover, diurnal profile of cortisol levels and 24-hour urinary free cortisol (UFC) were assessed. ALL survivors underwent a test with 1 ug of synthetic ACTH. RESULTS: The study revealed lower level of PRA (1.94±0.98 ng/mL/h vs 3.61±4.85 ng/mL/h, p=0.029) and higher FBG (4.6±0.38 mmol/L vs 4.41±0.39 mmol/L, p=0.018) in the ALL group compared to controls. UFC correlated with evening cortisol (p=0.015, r=0.26), midnight cortisol (p=0.002, r=0.33), and DHEA-S (p=0.004, r=0.32). UFC also correlated with systolic and diastolic blood pressure (p=0.033, r=0.23 and p=0.005, r=0.31, respectively). The ACTH test confirmed impaired adrenal function in 4/43 ALL survivors (9%). Two of the patients who needed permanent hydrocortisone replacement had low UFC, midnight cortisol and DHEA-S levels. CONCLUSION: These results highlight the importance of reviewing adrenal gland functionality after chemo/radiotherapy in ALL survivors. DHEA-S proved to be a good marker to assess the adrenal glands after oncological therapy. Post-treatment disturbances of the adrenal axis could be associated with metabolic complications.
format Online
Article
Text
id pubmed-9724047
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-97240472022-12-12 The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia Hull, Barbara Wędrychowicz, Anna Ossowska, Magdalena Furtak, Aleksandra Badacz, Joanna Skoczeń, Szymon Starzyk, Jerzy B. J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment. METHODS: Forty-three ALL survivors, mean age 8.5±3.6 years and 45 age and sex-matched healthy controls were recruited to the study. ALL patients were assessed once within five years following oncological treatment completion. Fasting blood samples were collected from all participants to measure: fasting blood glucose (FBG); cortisol; aldosterone; plasma renin activity (PRA); dehydroepiandrostendione-sulfate (DHEA-S); and adrenocorticotropic hormone (ACTH). Moreover, diurnal profile of cortisol levels and 24-hour urinary free cortisol (UFC) were assessed. ALL survivors underwent a test with 1 ug of synthetic ACTH. RESULTS: The study revealed lower level of PRA (1.94±0.98 ng/mL/h vs 3.61±4.85 ng/mL/h, p=0.029) and higher FBG (4.6±0.38 mmol/L vs 4.41±0.39 mmol/L, p=0.018) in the ALL group compared to controls. UFC correlated with evening cortisol (p=0.015, r=0.26), midnight cortisol (p=0.002, r=0.33), and DHEA-S (p=0.004, r=0.32). UFC also correlated with systolic and diastolic blood pressure (p=0.033, r=0.23 and p=0.005, r=0.31, respectively). The ACTH test confirmed impaired adrenal function in 4/43 ALL survivors (9%). Two of the patients who needed permanent hydrocortisone replacement had low UFC, midnight cortisol and DHEA-S levels. CONCLUSION: These results highlight the importance of reviewing adrenal gland functionality after chemo/radiotherapy in ALL survivors. DHEA-S proved to be a good marker to assess the adrenal glands after oncological therapy. Post-treatment disturbances of the adrenal axis could be associated with metabolic complications. Galenos Publishing 2022-12 2022-12-01 /pmc/articles/PMC9724047/ /pubmed/35633644 http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2 Text en ©Copyright 2022 by Turkish Pediatric Endocrinology and Diabetes Society | The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hull, Barbara
Wędrychowicz, Anna
Ossowska, Magdalena
Furtak, Aleksandra
Badacz, Joanna
Skoczeń, Szymon
Starzyk, Jerzy B.
The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title_full The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title_fullStr The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title_full_unstemmed The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title_short The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
title_sort assessment of the hypothalamic-pituitary-adrenal axis after oncological treatment in pediatric patients with acute lymphoblastic leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724047/
https://www.ncbi.nlm.nih.gov/pubmed/35633644
http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2
work_keys_str_mv AT hullbarbara theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT wedrychowiczanna theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT ossowskamagdalena theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT furtakaleksandra theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT badaczjoanna theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT skoczenszymon theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT starzykjerzyb theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT hullbarbara assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT wedrychowiczanna assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT ossowskamagdalena assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT furtakaleksandra assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT badaczjoanna assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT skoczenszymon assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia
AT starzykjerzyb assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia